US FDA approves Lupin's generic dermatosis ointment
Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in
A Cloud Migration Plan for Corporations featuring Snowflake®
Investor Activism Campaigns Hit Record High in 2022
Essential IR Insights Newsletter - February 2023
Lupin Ltd. received final approval from the U.S. FDA to market its desoximetasone ointment USP, 0.05%, a generic equivalent of Taro Pharmaceutical Industries Ltd.'s Topicort Ointment.
The ointment is for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
